GPX4 and Alzheimer disease: Third, clinical efforts should include multicenter AD biobanks to validate associations between biomarkers such as ACSL4 and GPX4 and cognitive scores, as well as combined clinical trials of ferroptosis inhibitors with anti-Aβ monoclonal antibodies to examine therapeutic benefit in antibody-resistant patients.